Ahmedabad: Accord Plasma B V, a subsidiary of Intas Pharmaceuticals, has signed a definitive agreement to acquire Prothya Biosolutions Belgium BV and its subsidiaries, a leading European manufacturer of plasma-derived medicinal products (PDMPs).
The deal, subject to customary closing conditions and regulatory approvals, is expected to conclude soon.
The acquisition is a strategic milestone in Intas and Accord’s ambition to build a truly global presence in the PDMP sector, extending the company’s leadership in India to a robust international footprint.
Also Read: UDENYCA Acquired by Intas Pharmaceuticals and Accord BioPharma in Biosimilar Expansion
Prothya Biosolutions: Over Six Decades of Expertise in Plasma Collection
Founded through the 2021 merger of Plasma Industries Belgium (formerly associated with the Belgian Red Cross) and Sanquin Plasma Products (previously part of the Sanquin Blood Supply Foundation), Prothya Biosolutions has over six decades of expertise in plasma collection and PDMP production.
Headquartered in Amsterdam and Brussels, the company operates plasma collection centres across Hungary and employs approximately 1,200 people, making it one of Europe’s largest plasma fractionators.
Binish Chudgar, Chairman of Intas and Accord, stated: “We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. By combining our fractionation capabilities in India with Prothya’s European expertise, we are building a truly global plasma platform to serve patients worldwide with essential, often under-prescribed therapies.”
Intas has been active in the plasma industry since 2015, supplying hospitals in India with PDMPs and exporting to international markets. Its Gujarat-based facility currently boasts an annual fractionation capacity of over 1 million litres, with further expansion underway.
Also Read: CATCH Grant Program Offers AI Innovators in Cancer Care up to INR 1 Crore in Funding
Nir Epstein, CEO of Prothya Biosolutions, added: “Over the past four years, we’ve entered new markets, advanced life-saving therapies, and built a strong plasma collection network in Hungary. Accord is the right partner to take Prothya to the next stage of growth and global expansion.”
The PDMP market – particularly for intravenous immunoglobulin (IVIG)—is valued at $30 billion and projected to reach $50 billion by 2035. This acquisition provides Intas with enhanced fractionation capacity and access to Accord’s commercial network across 85 countries.
BofA Securities is acting as exclusive financial advisor to Accord, while Evercore is serving as exclusive financial advisor to Prothya Biosolutions.
